Saturday 10 October 2026
Export all IDXG data to Excel Powerpack
Interpace Biosciences, Inc.
IDXG
Interpace Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.7 million, down 17.5% from fiscal 2024. In the quarter to June 2026, revenue fell 1.09%, EPS grew 104.1% and free cash flow fell 92.1%, each against the same quarter a year earlier. Operating cash flow growth for five consecutive years.
6.00
0.00
0.00%
Follow IDXG
Interpace Biosciences, Inc. (IDXG) P/E ratio
As of 9 October 2026, Interpace Biosciences, Inc. (IDXG) trades at a P/E ratio of 0.2×. Over the past ten years it has ranged from 0.0× (January 2026) to 0.5× (November 2024); the current reading is higher than 66% of that period.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | (89.46%) |
| FY2024 | 0.4× | 70.60% |
| FY2023 | 0.2× | 0.00% |
| FY2022 | 0.2× | 0.00% |
| FY2021 | 0.2× | 0.00% |
| FY2020 | 0.2× | 0.00% |
| FY2019 | 0.2× | 0.00% |
| FY2018 | 0.2× | 0.00% |
| FY2017 | 0.2× | 0.00% |
| FY2016 | 0.2× | 0.00% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.1× | (16.16%) |
| Mar 2026 | 0.1× | 63.80% |
| Dec 2025 | 0.0× | (78.71%) |
| Sep 2025 | 0.2× | 31.06% |
| 42 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.5×
Ten-year median
0.2×
Current reading's percentile
66
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IDXG Interpace Biosciences, Inc. | 0.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)